MedTrace Logo

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

NCT00046176 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2020-03-24

No results posted yet for this study

Summary

This study is a 48-week study designed to evaluate the safety and efficacy of a fixed-dose combination tablet administered once-a-day versus the individual tablets administered twice-a-day within 3-drug combination regimens in ART (antiretroviral)-experienced HIV-1 infected patients.

Conditions

  • Infection, Human Immunodeficiency Virus I
  • HIV Infection

Interventions

DRUG

abacavir/lamivudine

DRUG

abacavir

DRUG

lamivudine

Sponsors & Collaborators

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials, MD · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-26
Primary Completion
2004-05-17
Completion
2004-05-17

Countries

  • United States
  • Costa Rica
  • Panama
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00046176 on ClinicalTrials.gov